obinutuzumab: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
obinutuzumab: clinical details
Prescribing considerations
- Administer under an experienced physician with immediate access to full resuscitation facilities.
- Assess infusion-reaction and tumour-lysis risk; provide indicated premedication, hydration and urate-lowering prophylaxis.
- Record the product name and batch number for biological traceability.
- Review active, chronic or recurrent infection, cardiac or pulmonary disease, renal impairment, vaccination needs and concomitant medicines.
- Consider the benefit and risk of temporarily withholding antihypertensives around infusion.
Contraindications and cautions
- Hypersensitivity to obinutuzumab or an excipient.
- Do not administer in the presence of an active infection.
- Patients with active hepatitis B disease should not receive treatment.
Monitoring
- Screen every patient for hepatitis B surface antigen and core antibody before treatment; manage positive serology with appropriate specialist input.
- Monitor full blood count, particularly neutrophils and platelets; delayed or prolonged neutropenia can occur.
- For tumour-lysis risk, monitor renal function, potassium, uric acid and other relevant chemistry.
- Monitor blood pressure and cardiorespiratory status during and after infusion, especially with pre-existing disease.
- Assess promptly for serious infection, hepatitis reactivation, bleeding, immunoglobulin reduction and new neurological symptoms suggesting PML.
Clinical pharmacology
Obinutuzumab is a glycoengineered, humanised Type II IgG1 anti-CD20 antibody. It causes direct cell death and promotes antibody-dependent cellular cytotoxicity and phagocytosis, with relatively limited complement-dependent cytotoxicity. Clearance is partly target-mediated and changes as circulating CD20-positive cells are depleted.
Formulation and product differences
- The selected UK product is a single-use concentrate for intravenous infusion that must be diluted by a healthcare professional.
- It must not be given as an intravenous push or bolus.
- The concentrate is colourless to slightly brown and contains histidine, trehalose, poloxamer 188 and water for injections.
obinutuzumab preparations and strengths
Solution for infusion
Route: Intravenous
Strengths: 1000 mg
obinutuzumab interactions
Formal interaction studies are limited, so the clinical team should review prescribed, over-the-counter and herbal products.
Live viral vaccines
Avoid during treatment and until B-cell recovery because obinutuzumab suppresses B cells and vaccine safety or effectiveness may be reduced.
Antihypertensive medicines
Blood pressure can fall during infusion, so the treating team may temporarily alter their use after assessing the risk of hypertension.
Anticoagulants and platelet inhibitors
These may worsen bleeding if obinutuzumab causes thrombocytopenia, requiring individual review and closer monitoring.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.